Merck & Co., Inc. Sees Unusually High Options Volume (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) was the recipient of unusually large options trading activity on Wednesday. Traders bought 68,587 call options on the stock. This represents an increase of approximately 188% compared to the typical volume of 23,838 call options.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MRK shares. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research note on Wednesday, August 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Fifteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.50.

Merck & Co., Inc. Stock Performance

NYSE MRK traded up $15.68 on Wednesday, hitting $150.85. 21,169,461 shares of the company’s stock traded hands, compared to its average volume of 10,722,418. The firm’s 50-day moving average price is $126.19 and its two-hundred day moving average price is $120.43. The firm has a market capitalization of $372.16 billion, a PE ratio of 120.51, a P/E/G ratio of 5.86 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $151.82.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Insider Activity

In related news, EVP David Michael Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. BlackRock Inc. increased its holdings in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after buying an additional 1,073,507 shares in the last quarter. State Street Corp increased its holdings in Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after buying an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after acquiring an additional 249,110 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination met the trial’s primary endpoint by significantly extending recurrence-free survival versus Keytruda alone and also reduced the risk of melanoma spreading to distant parts of the body. The results represent the first positive late-stage validation of an mRNA cancer vaccine and could expand Keytruda’s long-term growth opportunity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The announcement generated unusually strong investor interest, with Merck options traders purchasing 68,587 call contracts—about 188% above average daily call volume—suggesting increased bullish positioning. Moderna Rockets, Merck Jumps as Melanoma Therapy Meets Primary Goal
• Neutral Sentiment: Analysts and investors are awaiting complete trial data, including the magnitude and durability of the benefit, safety results, regulatory filings and potential commercialization details. The initial findings are encouraging but do not yet establish the vaccine’s ultimate financial contribution. Melanoma vaccine data boosts outlook, analysts await full results
• Neutral Sentiment: One valuation review characterized Merck at roughly $135.97 as fairly valued, indicating that some of the vaccine optimism may already be reflected in the stock following its move to a new one-year high. Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.